Cartesian Therapeutics (RNAC) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$1.5M

Revenue (quarter)

—

Revenue growth (year over year)

—

Gross profit (trailing twelve months)

$1.5M

Gross margin

100.00%

Net income (trailing twelve months)

−$151.9M

Net income (quarter)

$15.8M

Net income growth (year over year)

−0.74%

Net margin

−10283.75%

Return on equity

—

EPS (trailing twelve months)

−$5.78

Book value per share

−$4.17

P/E (trailing twelve months)

—

Price to book

—

Debt to assets

139.30%

Payout ratio

—

Dividend yield

—

Company profile

Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering cell therapy for the treatment of autoimmune diseases. The company uses technology and a manufacturing platform to introduce mRNA into cells to provide a therapeutic effect to patients suffering from a variety of autoimmune conditions. Unlike DNA, mRNA degrades naturally over time without integrating into the cell's genetic material.

• Is Cartesian Therapeutics (RNAC) profitable?

  No. Cartesian Therapeutics reported a net loss of $151.9M over the trailing twelve months.

• How much revenue does Cartesian Therapeutics (RNAC) make?

  Cartesian Therapeutics generated $1.5M in revenue over the trailing twelve months.

• How do I buy stock in Cartesian Therapeutics (RNAC)?

  RNAC trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.